Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch.
about
The use of drugs in patients who have undergone bariatric surgeryTrends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes.Vitamin, mineral, and drug absorption following bariatric surgeryLong-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin.Treatment of lipid disorders in obesity.Pharmacokinetic effects of bariatric surgery.Impact of obesity on drug metabolism and elimination in adults and children.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.The influence of bypass procedures and other anatomical changes in the gastrointestinal tract on the oral bioavailability of drugs.Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes.Review article: The nutritional and pharmacological consequences of obesity surgery.Psychopharmacology and Bariatric Surgery.Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations.Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine.Protein Abundance of Clinically Relevant Drug-Metabolizing Enzymes in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens.Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach.Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL).
P2860
Q33633328-C81208F8-76F1-41B0-86AF-BF58F73B66D6Q36390234-766C26BA-1E41-43C1-8909-6FA7CA42BB6DQ36608087-5D497ACE-6C34-4C1E-9EEC-BC949494D738Q36865856-F65636A7-3DA4-470C-B41E-137E7C1D5CF5Q37923978-3AF42C2D-CF8B-4AC6-A0D1-6D825AF78307Q37970648-651267EE-EE06-4873-A7CA-96152A4AD4C0Q37997025-50E862FD-77B3-4F83-BAB0-7027A4AE3144Q38014312-D777737E-E36C-4B1D-B668-3CAEE33411E6Q38079182-C64C9EB9-750E-4D37-9C22-6AD136D9F5CDQ38083603-BAA7DF50-7231-4E55-986B-DFCC6ADBAD38Q38235543-DFF651E3-884B-4336-B4B3-A88ADD0B87B6Q38580433-FF30D44F-FBF8-4718-8C83-AD725D352714Q38874008-2AA4698A-B490-4ED4-96EA-DDA53768765BQ41454726-87B2A95B-5480-4701-8189-CF5D7E85C4AAQ47330563-133864EA-A6E3-4DC6-8C5A-DC7F03F98A2CQ48035659-C1F73E00-E92A-46AC-B87C-DB84F2CCD20BQ55330048-A2047AD5-6D74-43AC-888F-F62FAC2D3B0E
P2860
Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Significant increase in system ...... iversion with duodenal switch.
@en
Significant increase in system ...... iversion with duodenal switch.
@nl
type
label
Significant increase in system ...... iversion with duodenal switch.
@en
Significant increase in system ...... iversion with duodenal switch.
@nl
prefLabel
Significant increase in system ...... iversion with duodenal switch.
@en
Significant increase in system ...... iversion with duodenal switch.
@nl
P2093
P2860
P356
P1476
Significant increase in system ...... iversion with duodenal switch.
@en
P2093
G S Jakobsen
H Christensen
I B Skottheim
J Hjelmesaeth
K Stormark
P2860
P304
P356
10.1038/CLPT.2010.32
P407
P577
2010-05-05T00:00:00Z